Primary source: Inspections and Compliance
FDA approved Zanvastro (zilganersen) injection for treating Alexander disease in pediatric and adult patients, marking a significant new treatment option.
This approval provides the first targeted therapy for Alexander disease, addressing a previously unmet medical need and significantly improving the treatment landscape for affected patients.
Healthcare providers must implement the new administration protocol for Zanvastro, which is an injection every three months, and monitor for common side effects such as vomiting, back pain, and signs of aseptic meningitis.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Healthcare providers must implement the new administration protocol for Zanvastro, which is an injection every three months, and monitor for common side effects such as vomiting, back pain, and signs of aseptic meningitis.
The U.S. FDA has approved Zanvastro (zilganersen) injection for Alexander disease, the first therapy to target the underlying cause of this rare neurodegenerative condition. Patients aged 2 years and older can receive this treatment, which is administered every three months by a trained healthcare professional.
What changed: FDA approved Zanvastro (zilganersen) injection for treating Alexander disease in pediatric and adult patients, marking a significant new treatment option.
Why it matters: This approval provides the first targeted therapy for Alexander disease, addressing a previously unmet medical need and significantly improving the treatment landscape for affected patients.
Practical implication: Healthcare providers must implement the new administration protocol for Zanvastro, which is an injection every three months, and monitor for common side effects such as vomiting, back pain, and signs of aseptic meningitis.
Published from the regulator source ingestion pipeline after PV impact triage.
Stakeholders must familiarize themselves with the new data elements for Individual Case Safety Reports (ICSRs) as per the revised EudraVigilance access policy effective immediately.
Ensure that all labeling and safety information reflects the updated product name 'Prasugrel Viatris' instead of 'Prasugrel Mylan'.
The program will implement collaborative processes for the evaluation of technologies, enhancing real-world evidence integration into signal management and impacting regulatory compliance workflows.
Operational support will now be increased for disease surveillance, health worker assistance, and community outreach based on the new funding and response framework.
